Umbhali: Gregory Harris
Umhla Wokudalwa: 14 Utshazimpuzi 2021
Hlaziya Umhla: 24 Isilimela 2024
Anonim
Mode of action of Saccharomyces boulardii CNCM I-745
Ividiyo: Mode of action of Saccharomyces boulardii CNCM I-745

Umxholo

ISaccharomyces boulardii ligwele. Yayifudula ichongwa njengendidi eyahlukileyo yegwele. Ngoku kukholelwa ukuba bubunzima beSaccharomyces cerevisiae. Kodwa i-Saccharomyces boulardii yahlukile kwezinye iintlobo ze-Saccharomyces cerevisiae eyaziwa ngokuba yi-brewer’s yeast kunye ne-baker’s yeast. I-Saccharomyces boulardii isetyenziswa njengeyeza.

I-Saccharomyces boulardii ixhaphake kakhulu ekunyangeni nasekuthinteleni isifo sohudo, kubandakanya iintlobo ezosulelayo ezinje ngesifo sorhudo i-rotaviral ebantwaneni. Inobungqina bokusetyenziswa kwezinye iintlobo zorhudo, amabala, kunye nosulelo lokugaya olunokukhokelela kwizilonda.

Isifo seCoronavirus 2019 (COVID-19): Akukho bungqina bokuba uxhase usebenzisa i-Saccharomyces boulardii ye-COVID-19. Landela ukhetho lokuphila olusempilweni kunye neendlela zothintelo eziqinisekisiweyo endaweni yoko.

Amayeza endalo aVimba weDatha Ukusebenza kwexabiso ngokusekwe kubungqina besayensi ngokwala manqanaba alandelayo: Ukusebenza, ukusebenza ngokukuko, okunokwenzeka ukuba kusebenze, okungenzeka kungasebenzi, kunokwenzeka ukungasebenzi, ukungasebenzi, kunye nobungqina obungonelanga bokulinganisa.

Ukulinganiswa kokusebenza kwe IIMPAHLA ZEBAKALA BOULARDII zezi zilandelayo:


Kusenokwenzeka ukuba iyasebenza ...

  • Urhudo. Uphando lubonisa ukuba ukunika iSaccharomyces boulardii kubantwana abanesifo sohudo kunokunciphisa ukuba ithatha ixesha elingakanani ukuya kuthi ga kusuku olunye. Kodwa iSaccharomyces boulardii ibonakala ingasebenzi kangako kunamayeza aqhelekileyo kurhudo, anje nge-loperamide (Imodium).
  • Urhudo olubangelwa yi-rotavirus. Ukunikezela nge-Saccharomyces boulardii kwiintsana kunye nabantwana abanesifo sorhudo esibangelwa yi-rotavirus kunokunciphisa ukuba isifo sohudo sihlala ixesha elingakanani ngosuku.

Inokwenzeka ukuba isebenze ...

  • Amabala. Uphando lubonisa ukuba ukuthatha iSaccharomyces boulardii ngomlomo kunceda ukuphucula ukubonakala kwamabala.
  • Urhudo kubantu abathatha amayeza okubulala iintsholongwane. Uninzi lophando lubonisa ukuba iSaccharomyces boulardii inokunceda ekuthinteleni isifo sohudo kubantu abadala nasebantwaneni abaphathwa ngamayeza okubulala iintsholongwane. Kwizigulana ezingama-9-13 ziphathwe ngeSaccharomyces boulardii ngexesha lokunyanga ngamayeza okubulala iintsholongwane, umntu omnye omncinci uya kuba nesifo sohudo esinxulumene namayeza.
  • Usulelo lwe-gastrointestinal tract yi-bacteria ebizwa ngokuba yiClostridium difficile. Ukuthatha iSaccharomyces boulardii kunye namayeza okubulala iintsholongwane kubonakala ngathi kunceda ukuthintela urhudo olunxulumene neClostridium difficile ekuphindweni kubantu abanembali yokuphindeka. Ukuthatha iSaccharomyces boulardii kunye namayeza okubulala iintsholongwane kubonakala ngathi kunceda ukuthintela iziqendu zokuqala zorhudo olunxulumene neClostridium difficile. Kodwa iingcali azikukhuthazi ukusebenzisa iSaccharomyces yokuthintela iziqendu zokuqala.
  • Usulelo lokugaya olunokukhokelela kwizilonda (Helicobacter pylori okanye H. pylori). Ukuthatha i-Saccharomyces boulardii ngomlomo kunye nonyango oluqhelekileyo H. pylori kuyanceda ukunyanga esi sifo. Malunga nabantu abali-12 kufuneka baphathwe nge-Saccharomyces boulardii eyongezelelweyo kwisigulana esinye ebesiya kuhlala sosulelekile ukuze sinyangeke. Ukuthatha i-Saccharomyces boulardii ikwanceda ukunqanda iziphumo ebezingalindelekanga ezinje ngesifo sorhudo kunye nesicaphucaphu esenzeka ngonyango oluqhelekileyo lwe-H. Pylori. Oku kunokunceda abantu bagqibe unyango lwabo oluqhelekileyo ku-H. Pylori.
  • Urhudo kubantu abane-HIV / AIDS. Ukuthatha i-Saccharomyces boulardii ngomlomo kubonakala ngathi kunciphisa urhudo olunxulumene ne-HIV.
  • Isifo esibi emathunjini kwiintsana ezingaphambi kwexesha (i-necrotizing enterocolitis okanye i-NEC). Uninzi lophando lubonisa ukuba ukunika iSaccharomyces boulardii ukukhawulezisa iintsana kuthintela i-NEC.
  • Urhudo lwabahambi. Ukuthatha i-Saccharomyces boulardii ngomlomo kubonakala kuthintela urhudo lwabahambi.

Kusenokwenzeka ukuba ayisebenzi ...

  • Usulelo lwegazi (sepsis). Uphando lubonisa ukuba ukunika iSaccharomyces boulardii ukukhawulezisa iintsana akuthinteli i-sepsis.

Akukho bungqina baneleyo bokulinganisa ukusebenza ...

  • Usulelo lwamathumbu olubangela urhudo (ikholera). I-Saccharomyces boulardii ibonakala ngathi ayiziphuculi iimpawu zekholera, nokuba inikwe unyango oluqhelekileyo.
  • Imemori kunye nezakhono zokucinga (umsebenzi wokuqonda). Uphando lwakwangoko lubonisa ukuba ukuthatha iSaccharomyces boulardii akuncedi abafundi benze ngcono kwiimviwo okanye kunciphise uxinzelelo.
  • Uhlobo lwesifo sokukrala kwamathumbu (isifo seCrohn). Ukuthatha iSaccharomyces boulardii kubonakala ngathi kunciphisa inani lokuhamba kwamathumbu kubantu abanesifo seCrohn. Uphando lwakwangoko lukwabonisa ukuba ukuthatha iSaccharomyces boulardii kunye ne-mesalamine kunokunceda abantu abanesifo seCrohn bahlale kuxolelo ixesha elide. Kodwa ukuthatha iSaccharomyces boulardii yodwa akubonakali kunceda abantu abanesifo seCrohn ukuba bahlale bexolelwe ixesha elide.
  • Icystic fibrosis. Uphando lwakwangoko lubonisa ukuba ukuthatha iSaccharomyces boulardii ngomlomo akulunciphisi usulelo lwegwele kwindawo yokugaya abantu abane-cystic fibrosis.
  • Ukumelwa yintliziyo. Uphando lwakwangoko lubonisa ukuba ukuthatha iSaccharomyces boulardii kunokuphucula ukusebenza kwentliziyo kubantu abanesifo sentliziyo.
  • Cholesterol ephezulu. Uphando lwakwangoko lubonisa ukuba iSaccharomyces boulardii kubonakala ngathi ayichaphazeli amanqanaba e-cholesterol.
  • Ingxaki yexesha elide yamathumbu amakhulu ebangela iintlungu zesisu (isifo esiswini esinokucaphuka okanye i-IBS). Uphando lubonisa ukuba ukuthatha iSaccharomyces boulardii kuphucula umgangatho wobomi kubantu abanesifo sorhudo-ubukhulu okanye uhlobo lwe-IBS. Kodwa i-Saccharomyces boulardii ayibonakali iphucula uninzi lweempawu ze-IBS ezinjengeentlungu zesisu, ukungxamiseka, okanye ukudumba.
  • Usulelo lwamathumbu ngama-parasites. Uphando lwakwangoko lubonisa ukuba ukuthatha iSaccharomyces boulardii ngomlomo kunye namayeza okubulala iintsholongwane kunciphisa urhudo kunye nentlungu esiswini kubantu abanesifo se-amoeba.
  • Ukuthungwa kwesikhumba kwiintsana (i-neundatal jaundice). Abanye abantwana bakhula i-jaundice emva kokuzalwa ngenxa yamanqanaba aphezulu e-bilirubin. Ukunika i-Saccharomyces boulardii kwiikota zeentsana kunokuthintela i-jaundice kunye nokunciphisa isidingo sonyango lwe-phototherapy kwinani elincinci lolu sana. Kodwa ayaziwa ukuba i-Saccharomyces boulardii inciphisa umngcipheko we-jaundice kwiintsana ezisemngciphekweni. Ukunika i-Saccharomyces boulardii kwiintsana kunye ne-phototherapy akwehlisi amanqanaba e-bilirubin ngcono kune-phototherapy yodwa.
  • Iintsana ezizalwe zinobunzima obungaphantsi kwama-2500 gram (iiponti ezi-5, ii-ounces eziyi-8). Ukunika isongezelelo seSaccharomyces boulardii emva kokuzalwa kubonakala kuphucula ukutyeba kunye nokondla kwiintsana ezizelwe ngaphambi kwexesha ezinobunzima bokuzalwa obuncinci.
  • Ukukhula okuthe kratya kwebhaktheriya kumathumbu amancinci. Uphando lwakwangoko lubonisa ukuba ukongeza i-Saccharomyces boulardii kunyango ngamayeza okubulala iintsholongwane kunciphisa ukukhula kweentsholongwane emathunjini ngcono kune-antibiotics yodwa.
  • Uhlobo lwesifo sokukrala kwamathumbu (ulcerative colitis). Uphando lwakwangoko lubonisa ukuba ukongeza i-Saccharomyces boulardii kunyango olusemgangathweni lwe-mesalamine kunokunciphisa iimpawu kubantu abane-ulcerative colitis ethambileyo.
  • Izilonda zenqanawa.
  • Fever blister.
  • Imihlathi.
  • Ukunganyamezelani kweLactose.
  • Isifo seLyme.
  • Ubuhlungu bemisipha obubangelwa kukuzilolonga.
  • Usulelo lwe-Urinary tract (UTIs).
  • Usulelo lwegwele.
  • Ezinye iimeko.
Ubungqina obungakumbi buyafuneka ukukala i-Saccharomyces boulardii kwezi zinto zisetyenziswayo.

ISaccharomyces boulardii ibizwa ngokuba yi "probiotic," into enobuhlobo enceda ukulwa izinto ezibangela izifo emathunjini afana neentsholongwane kunye negwele.

Xa kuthathwa ngomlomo: Saccharomyces boulardii yi NGOKUKHUSELEKILEYO kubantu abadala abaninzi xa bethathwe ngomlomo ukuya kuthi ga kwiinyanga ezili-15. Ingabangela igesi kwabanye abantu. Rhoqo, kunokubangela usulelo lomngundo olunokusasazeka ngokuhamba kwegazi kuye kuwo wonke umzimba (fungemia).

Amanyathelo okhuseleko kunye nezilumkiso:

Ukukhulelwa kunye nokuncancisa: Akukho lwazi lwaneleyo lwanokuthenjwa lokwazi ukuba ngaba iSaccharomyces boulardii ikhuselekile ukusetyenziswa xa ukhulelwe okanye uncancisa. Hlala kwicala elikhuselekileyo kwaye uphephe ukusetyenziswa.

Abantwana: Saccharomyces boulardii yi UKHUSELEKO OLUNOKWENZEKA kubantwana xa bethathwe ngomlomo ngokufanelekileyo. Nangona kunjalo, urhudo ebantwaneni kufuneka kuvavanywe yingcali yezempilo ngaphambi kokusebenzisa iSaccharomyces boulardii.

Abantu abadala: Abantu abadala banokuba nomngcipheko owandayo wosulelo lokungunda xa uthatha iSaccharomyces boulardii. Hlala kwicala elikhuselekileyo kwaye uphephe ukusetyenziswa.

Amandla omzimba abuthathaka: Kukho inkxalabo yokuba ukuthatha iSaccharomyces boulardii kunokubangela i-fungemia, leyo bubukho begwele egazini. Elona nani lamatyala eSchcharomyces boulardii enxulumene nefungemia kunzima ukufumanisa. Nangona kunjalo, umngcipheko ubonakala ungowona mkhulu kubantu abagula kakhulu okanye abaye benza buthathaka amajoni omzimba. Ngokukodwa, abantu abane-catheters, abo bafumana ityhubhu yokondla, kunye nabo baphathwa ngamayeza amaninzi okanye ii-antibiotics ezisebenza kwiintlobo ezahlukeneyo zosulelo babonakala besemngciphekweni omkhulu. Kwiimeko ezininzi, i-fungemia ibangelwe kukungcoliseka kwe-catheter yomoya, umphezulu wendalo, okanye izandla ezingcoliswe yi-Saccharomyces boulardii.

Igwele lokungezwani komzimba: Abantu abanegwele lokungezwani komzimba banokungabikho komzimba kwiimveliso eziqukethe iSaccharomyces boulardii, kwaye bayacetyiswa ukuba baziphephe ezi mveliso.

Incinci
Jonga olu dibaniso.
Amayeza osulelo lokungunda (iAntifungals)
ISaccharomyces boulardii yfungus. Amayeza osulelo lokungunda anceda ukunciphisa ukungunda emzimbeni nasemzimbeni. Ukuthatha i-Saccharomyces boulardii ngamayeza osulelo lokungunda kunokunciphisa ukusebenza kweSaccharomyces boulardii.
Amanye amayeza osulelo lokungunda aquka i-fluconazole (Diflucan), icaspofungin (Cancidas), itraconazole (Sporanox) amphotericin (Ambisome), kunye nezinye.
Akukho kunxibelelana kwaziwayo kunye namayeza kunye nezongezo.
Akukho kunxibelelana kwaziwayo nokutya.
La machiza alandelayo afundwe kuphando lwezesayensi:

ABADALA

NGOMLOMO:
  • Ukuhanjiswa kwesisu kubantu abathatha ii-antibiotics (isifo sohudo esinxulumene ne-antibiotic)I-250-500 mg ye-Saccharomyces boulardii ithathwa amaxesha ama-2-4 imihla ngemihla ukuya kuthi ga kwiiveki ezi-2 ixhaphake kakhulu. Kwiimeko ezininzi, idosi yemihla ngemihla ayidluli kwi-1000 mg yonke imihla.
  • Usulelo lwephecana lesisu ngamabhaktheriya abizwa ngokuba yiClostridium difficileUkuthintela ukuphindaphinda, i-500 mg ye-Saccharomyces boulardii kabini yonke imihla kwiiveki ezi-4 kunye nonyango lwe-antibiotics lusetyenzisiwe.
  • Ukusuleleka kwintsholongwane engakhokelela kwizilonda (Helicobacter pylori okanye H. pylori): 500-1000 mg yeSaccharomyces boulardii yonke imihla kangangeeveki ezi-1-4 isetyenziswa kakhulu.
  • Urhudo kubantu abane-HIV / AIDS: Iigrama ezi-3 zeSaccharomyces boulardii mihla le.
  • Urhudo lwabahambi: 250-1000 mg ye-Saccharomyces boulardii mihla le kwinyanga e-1.
ABANTWANA

NGOMLOMO:
  • Ukuhanjiswa kwesisu kubantu abathatha ii-antibiotics (isifo sohudo esinxulumene ne-antibiotic)I-250 mg ye-Saccharomyces boulardii kube kanye okanye kabini ngemini ixesha lokusetyenziswa kwee-antibiotics.
  • YorhudoUkunyanga isifo sohudo, i-250 mg ye-Saccharomyces boulardii kube kanye okanye kabini yonke imihla okanye i-10 yezigidigidi zokwenza iikholoni kanye yonke imihla kangangeentsuku ezintlanu. Ukunyanga urhudo oluqhubekekayo, i-1750 yezigidigidi ukuya kwi-175 yezigidi zezigidi zeekoloni zokwenza i-Saccharomyces boulardii kabini yonke imihla kwiintsuku ezintlanu kuye kwasetyenziswa. Ukuthintela urhudo kubantu abafumana ukutya okwe-tube, i-500 mg ye-Saccharomyces boulardii isetyenziswe amaxesha amane mihla le.
  • Isifo sohudo esibangelwa yi-rotavirusKusetyenziswe i-200-250 mg ye-Saccharomyces boulardii kabini imihla ngemihla kwiintsuku ezi-5.
  • Kwisifo esibi samathumbu kwiintsana ezingaphambi kwexesha (i-necrotizing enterocolitis okanye i-NEC): 100-200 mg / kg Saccharomyces boulardii yonke imihla, ukuqala kwiveki yokuqala emva kokuzalwa.
Iprobiotic, iProbiotique, iSaccharomyces, iSaccharomyces Boulardii CNCM I-745, iSaccharomyces Boulardii HANSEN CBS 5926, Saccharomyces Boulardii Lyo CNCM I-745, Saccharomyces Boulardius, Saccharomyces Cerevisiae Boulardii, Sacchomyomy Caseschomyosia) ICerevisiae HANSEN CBS 5926, Saccharomyces cerevisiae var boulardii, S. Boulardii, SCB.

Ukuze ufunde okungakumbi malunga nokubhalwa kweli nqaku, nceda ubone Amayeza endalo aVimba weDatha indlela yokusebenza.


  1. Isazisi seFlorez, iVeroniki AA, iAl Khalifah R, et al. Ukuthelekisa ukusebenza kunye nokukhuseleka kongenelelo lwesifo sorhudo olunamandla kunye ne-gastroenteritis ebantwaneni: Uphengululo lwenkqubo kunye nohlalutyo lweemeta zenethiwekhi. Inye. 2018; 13: e0207701. Jonga i-abstract.
  2. IHarnett JE, uPyne DB, uMcKune AJ, uPenm J, uPumpa KL. Ukongezwa kweprobiotic kuphakamisa utshintsho olulungileyo kubuhlungu bemisipha kunye nomgangatho wokulala kubadlali bombhoxo. J Sci Med Ezemidlalo. Ngo-2020: S1440-244030737-4. Jonga i-abstract.
  3. UGao X, uWang Y, uShi L, uFeng W, u-Yi K. Iziphumo kunye nokukhuseleka kwe-Saccharomyces boulardii ye-neonatal necrotizing enterocolitis kwiintsana zaphambi kwexesha: Ukuphononongwa ngokuchanekileyo kunye nokuhlaziywa kwemeta. J Trop Pediatr. Ngo-2020: fmaa022. Jonga i-abstract.
  4. UMourey F, u-Sureja V, uKheni D, et al. Isilingo se-Saccharomyces boulardii kwiintsana kunye nabantwana abanesifo sorhudo. Ukunyanga isifo sePediatr Dis J. 2020; 39: e347-e351. Jonga i-abstract.
  5. IKarbownik MS, Kr & eogon; czy & nacute; ska J, Kwarta P, et al. Iziphumo zokuncedisa ngeSaccharomyces boulardii ekusebenzeni koviwo lwezifundo kunye noxinzelelo olunxulumene noko kubafundi bezonyango abasempilweni: Uvavanyo olulawulwa ngokungahleliwe, oluyimfama kabini, olulawulwa yi-placebo. Izondlo. Ngo-2020; 12: 1469. Jonga i-abstract.
  6. UZhou BG, Chen LX, Li B, Wan LY, Ai YW. I-Saccharomyces boulardii njengonyango olusebenzayo lwe-Helicobacter pylori yokupheliswa: Ukuphononongwa ngokuchanekileyo kunye nohlalutyo lwe-meta nohlalutyo lokulandelelana kwetyala. Helicobacter. 2019; 24: e12651. Jonga i-abstract.
  7. USzajewska H, ​​uKolodziej M, uZalewski BM. Uphengululo lwenkqubo kunye nohlalutyo lwe-meta: Saccharomyces boulardii yokunyanga i-gastroenteritis ebukhali ebantwaneni-uhlaziyo lwe2020. Ndlela Pharmacol Ther. 2020. Jonga okungaqondakaliyo.
  8. USeddik H, uBoutallaka H, ​​uElkoti I, et al. I-Saccharomyces boulardii CNCM I-745 kunye nonyango olulandelelanayo lwe-Helicobacter pylori usulelo: uvavanyo olungenamkhawulo, oluvulekileyo lweelebheli. I-Eur J Clin Pharmacol. Ngo-2019; 75: 639-645. Jonga i-abstract.
  9. UGarcía-Collinot G, uMadrigal-Santillán EO, uMartínez-Bencomo MA, et al. Ukusebenza kwe-Saccharomyces boulardii kunye neMetronidazole yokuGqithisa kweBacterial encinci kwi-Systemic Sclerosis. IDig Dis Sci. 2019. Jonga okungaqondakaliyo.
  10. UMcDonald LC, uGerding DN, uJohnson S, et al .; Izifo ezosulelayo zoMbutho waseMelika. Izikhokelo zokuziqhelanisa neklinikhi yosulelo lweClostridium difficile kubantu abadala nasebantwaneni: Uhlaziyo luka-2017 nguMbutho weSifo seNtsholongwane waseMelika (i-IDSA) kunye noMbutho wezeMpilo kwi-Epidemiology yaseMelika (SHEA). Izifo ezosulelayo zeKlinikhi 2018; 66: e1-e48.
  11. UXu L, uWang Y, uWang Y, et al. Isilingo esenziwe imfama kabini ngokukhula kunye nokunyamezelana nokondla ngeSaccharomyces boulardii CNCM I-745 kwifomula ezondliweyo zentsana. J Isidumbu (iRio J). Ngo-2016; 92: 296-301. Jonga i-abstract.
  12. USheele J, uCartowski J, uDart A, et al. I-Saccharomyces boulardii kunye ne-bismuth subsalicylate njengongenelelo lwexabiso eliphantsi ukunciphisa ixesha kunye nobukrakra bekholera. Impilo yePathog Glob. Ngo-2015; 109: 275-82. Jonga i-abstract.
  13. URyan JJ, uHanes DA, uSchafer MB, uMikolai J, uZwickey H. Iziphumo zeProbiotic Saccharomyces boulardii kwiCholesterol kunye neLipoprotein Particles kwiHypercholesterolemic yabantu abadala: Ingalo enye, isifundo seLebhu evulekileyo. J Enye into yokuGqibezela iMed. Ngo-2015; 21: 288-93. Jonga i-abstract.
  14. I-Flatley EA, i-Wilde AM kunye ne-Nailor MD. I-Saccharomyces boulardii yokuthintela ukusuleleka kwesibhedlele isifo seClostridium difficile. J Isisu sesisu seDis. Ngo-2015; 24: 21-4. Jonga i-abstract.
  15. U-Ehrhardt S, uGuo N, uHinz R, et al. I-Saccharomyces boulardii yokuThintela isifo sohudo esiDityaniswa neAntibiotic: Uvavanyo olulawulwa ngokuRhabaxa, oluMnyama kabini, olulawulwa yiPlacebo. Vula iqonga leNtsholongwane. Ngo-2016; 3: ye011. Jonga i-abstract.
  16. UDinleyici EC, uKara A, uDalgic N, et al. I-Saccharomyces boulardii CNCM I-745 inciphisa ixesha lokurhuda, ubude bonyango olungxamisekileyo kunye nokuhlala esibhedlele kubantwana abanesifo sohudo. Uncedo lweeMicrobes. Ngo-2015; 6: 415-21. Jonga i-abstract.
  17. UDauby N. Imingcipheko yeSaccharomyces boulardii-Equlathe iiProbiotic zoThintelo lweClostridium difficile losulelo kubantu abadala. Gastroenterology. Ngo-2017; 153: 1450-1451. Jonga i-abstract.
  18. UCottrell J, uKoenig K, uPerfekt R, uHofmann R; Iqela leLoperamide-Simethicone Acute diarrhea. Ukuthelekiswa kweefom ezimbini zeLoperamide-Simethicone kunye neProbiotic Yeast (Saccharomyces boulardii) kunyango lweTyhuna eliBukhali kubantu abadala: Uvavanyo lweKlinikhi olungalindelekanga. Iziyobisi R D. 2015; 15: 363-73. Jonga i-abstract.
  19. ICostanza AC, Moscavitch SD, Faria Neto HC, Mesquita ET. Unyango lweprobiotic kunye neSaccharomyces boulardii yezigulana ezingaphumeleli kwintliziyo: uvavanyo olungenamsebenzi, oluyimfama, olulawulwa yi-placebo. Int J Cardiol. Ngo-2015; 179: 348-50. Jonga i-abstract.
  20. UCarstensen JW, uChehri M, uSchønning K, et al. Ukusetyenziswa kweprophylactic Saccharomyces boulardii ukuthintela usulelo lweClostridium difficile kwizigulana ezibhedlele: isifundo esilawulwayo esinokwenzeka. I-Eur J yeKlinikhi yeMicrobiol eyosulele iDis. 2018; 37: 1431-1439. Jonga i-abstract.
  21. Asmat S, Shaukat F, Asmat R, Bakhat HFSG, Asmat TM. Ukusebenza ngempumelelo kweKlinikhi yokuThelekisa kweSaccharomyces Boulardii kunye neLactic Acid njengeProbiotic kwiAtute Pediatric Diarrhea. J Coll Amagqirha oGqirha Pak. 2018; 28: 214-217. Jonga i-abstract.
  22. URemenova T, uMorand O, uAmato D, uChadha-Boreham H, uTurutani S, uMarquardt T.Ulingo olulawulwa kabini, olungenamkhethe, olulawulwa yi-placebo lufunda ngeziphumo zeSaccharomyces boulardii kunyamezelo lwesisu, ukhuseleko, kunye ne-pharmacokinetics yemiglustat. I-Orphanet J Rare Dis 2015; 10: 81. Jonga i-abstract.
  23. ISuganthi V, iDas AG. Indima yeSaccharomyces boulardii ukunciphisa i-neonatal hyperbilirubinemia. J Uvavanyo lweKlinikhi yokuHlola ngo-2016; 10: SC12-SC15. Jonga i-abstract.
  24. URiaz M, uAlam S, uMalik A, uAli SM. Ukusebenza kunye nokukhuseleka kweSaccharomyces boulardii kwisifo sorhudo esibuhlungu somntwana: ityala elilawulwa ngokungahleliwe elingaboniyo. I-Indian J iPediatr 2012; 79: 478-82. Jonga i-abstract.
  25. -Corrêa NB, uPenna FJ, uLima FM, uNicoli JR, uFilimu LA. Unyango lohudo olubi kunye ne-Saccharomyces boulardii kwiintsana. J Isicombululo seGastroenterol Nutrition 2011; 53: 497-501. Jonga i-abstract.
  26. UCohen SH, uGerding DN, uJohnson S, et al .; Umbutho wezeMpilo kwi-Epidemiology yaseMelika; Izifo ezosulelayo zoMbutho waseMelika. Izikhokelo zokuziqhelanisa neklinikhi yosulelo lweClostridium difficile kubantu abadala: uhlaziyo luka-2010 luluntu kunyango lwezifo zaseMelika (SHEA) kunye noluntu lwezifo ezosulelayo eMelika (IDSA). Ulawulo lweNtsholongwane ye-Hosp Epidemiol 2010; 31: 431-55. Jonga i-abstract.
  27. IGoldenberg JZ, Ma SS, uSaxton JD, et al. Iiprobiotic zokuthintela isifo sohudo esihambelana neClostridium difficile kubantu abadala nasebantwaneni. Isiseko sedatha yeCochrane Isityhi sika-2013; CD006095. Jonga i-abstract.
  28. ILau CS, iChamberlain RS. Iiprobiotic ziyasebenza ekuthinteleni isifo sohudo esihambelana neClostridium difficile: uphononongo olucwangcisiweyo kunye nohlalutyo lweemeta. Int J Gen iMed. Ngo-2016; 9: 27-37. Jonga i-abstract.
  29. URoy U, uJessani LG, uRudramurthy SM, et al. Amatyala asixhenxe eSaccharomyces fungaemia ahambelana nokusetyenziswa kweprobiotic. Iimpawu ze2017; 60: 375-380. Jonga i-abstract.
  30. Romanio MR, Coraine LA, Maielo VP, Abramczyc ML, Souza RL, Oliveira NF. I-Saccharomyces cerevisiae fungemia kwisigulana sabantwana emva konyango lweprobiotic. UMfu Paul Pediatr 2017; 35: 361-4. Jonga i-abstract.
  31. UPozzzoni P, uRiva A, uBellatorre AG, et al. I-Saccharomyces boulardii yokuthintela isifo sorhudo esihambelana nezifo kwizigulana zabantu abadala ezibhedlele: iziko elinye, elingenamntu, elingaboniyo, elilawulwa yi-placebo. NdinguJ Gastroenterol 2012; 107: 922-31. Jonga i-abstract.
  32. UMartin IW, uTonner R, uTrivedi J, et al. I-Saccharomyces boulardii probiotic-enxulumene ne-fungemia: ukubuza ukhuseleko lale ndlela yokusetyenziswa kweprobiotic. Ukuchonga iMicrobiol Infect Dis. Ngo-2017; 87: 286-8. Jonga i-abstract.
  33. Choi CH, Jo SY, Ipaki HJ, Chang SK, Byeon JS, Myung SJ. Isilingo esingahleliwe, esingaboni kabini, esilawulwa yi-placebo se-Saccharomyces boulardii kwisifo esinganyangekiyo samathumbu: isiphumo kumgangatho wobomi. J Klinikhi yeGastroenterol. Ngo-2011; 45: 679-83. Jonga i-abstract.
  34. UAtici S, uSoysal A, uKaradeniz Cerit K, et al. Unyango lweCatheter olunxulumene neSaccharomyces cerevisiae Fungemia Emva koNyango lweProbiotic ye-Saccharomyces boulardii: Kumntwana okwigumbi labagula kakhulu kunye nokuphononongwa koncwadi. I-Med Mycol Case Rep. 2017; 15: 33-35. Jonga i-abstract.
  35. U-Appel-da-Silva MC, uNarvaez GA, uPerez LRR, uDrehmer L, uLebgoy J. Saccharomyces cerevisiae var. i-boulardii fungemia elandela unyango lweprobiotic. I-Med Mycol Case Rep. 2017; 18: 15-7. Jonga i-abstract.
  36. I-Chang HY, i-Chen JH, i-Chang JH, i-Lin HC, i-Lin CY, i-Peng CC. Iindidi ezininzi zeeprobiotiki zibonakala njengeyona ndlela isebenzayo kuthintelo lwe-necrotizing enterocolitis kunye nokufa: Uhlalutyo lweemeta oluhlaziyiweyo. Inye. Ngo-2017; 12: e0171579. Jonga i-abstract.
  37. I-Blaabjerg S, i-Artzi DM, i-Aabenhus R. Iiprobiotic zoThintelo lwe-Antibiotic-Associated Diarrhea kwizigulana ezingaphandle-Uvavanyo oluCwangcisiweyo kunye neMeta-Uhlalutyo. Amayeza okubulala iintsholongwane (iBasel). Ngo-2017; 6. Jonga i-abstract.
  38. IAl Faleh K, Anabrees J.Iiprobiotiki zokuthintela ukungena kwi-neocolotitis kwiintsana ezizelwe ngaphambi kwexesha. Isiseko sedatha yeCochrane Isityhi sika-2014; CD005496. Jonga i-abstract.
  39. Umsebenzi weS, Gupta PK, Das RR. Ukusebenza kunye noKhuseleko lweSaccharomyces boulardii kwiAcute Rotavirus Urhudo: Uvavanyo oluPhindwe kabini oluLawulwayo oluLungelelanisiweyo oluvela kwilizwe eliKhulayo. J Trop Pediatr. Ngo-2016; 62: 464-470. Jonga i-abstract.
  40. IGoldenberg JZ, uLytvyn L, uSteurich J, uParkin P, uMahant S, uJohnston BC. Iiprobiotic zokuthintela isifo sorhudo esihambelana nabantwana. Isiseko sedatha yeCochrane Isityhi 2015; CD004827. Jonga i-abstract.
  41. I-Feizizadeh S, Salehi-Abargouei A, Akbari V. Ukusebenza kunye nokukhuseleka kweSaccharomyces boulardii yesifo sorhudo. IPediatrics. Ngo-2014; 134: e176-191. Jonga i-abstract.
  42. USzajewska H, ​​Horvath A, Kolodziej M.Uphononongo lwenkqubo kunye nohlalutyo lwe-meta: Saccharomyces boulardii supplementation kunye nokupheliswa kosulelo lweHelicobacter pylori. Ndlela Pharmacol Ther. Ngo-2015; 41: 1237-1245. Jonga i-abstract.
  43. I-Szajewska H, ​​i-Kolodziej M. Uphengululo lwenkqubo kunye nohlalutyo lwe-meta: Saccharomyces boulardii kuthintelo lwe-anti-anti-diarrhea edibeneyo. Ndlela Pharmacol Ther. 2015; 42: 793-801. Jonga i-abstract.
  44. U-Ellouze O, uBerthoud V, uMervant M, uParthiot JP, uGirard C. Umothuko we-Septic ngenxa yeSacccaromyces boulardii. Uncedo lweMed Mal. Ngo-2016; 46: 104-105. Jonga i-abstract.
  45. IBafutto M, et al. Unyango lwesifo sorhudo-esisifo esinganyanzelekanga sesisu kunye ne-mesalamine kunye / okanye iSaccharomyces boulardii. IArq Gastroenterol. Ngo-2013; 50: 304-309. Jonga i-abstract.
  46. IBourreille A, et al. ISaccharomyces boulardii ayikuthinteli ukubuyela kwesifo sikaCrohn. KwiKlinikhi yeGastroenterol Hepatol. Ngo-2013; 11: 982-987.
  47. Serce O, Gursoy T, Ovali F, Karatekin G. Iziphumo zeSaccaromyces boulardii kwi-neonatal hyperbilirubinemia: ityala elilawulwa ngokungahleliwe. NdinguJ Perinatol. Ngo-2015; 30: 137-142. Jonga i-abstract.
  48. IVidelock EJ, iCremonini F. Uhlalutyo lweMeta: Iiprobiotiki kuhudo olunxulunyaniswa namayeza. Ndlela Pharmacol Ther. Ngo-2012; 35: 1355-69. Jonga i-abstract.
  49. IHempel S, Newberry SJ, Maher AR, uWang Z, uMiles JN, uShanman R, uJohnsen B, uShekelle PG. Iiprobiotic zothintelo kunye nonyango lwesifo sorhudo esihambelana namayeza: ukuphononongwa ngokuchanekileyo kunye nohlalutyo lweemeta. JAMA. Ngo-2012 9; 307: 1959-69. Jonga i-abstract.
  50. U-Elmer GW, uMoyer KA, uVega R, kunye no-al. Uvavanyo lweSaccharomyces boulardii yezigulana ezinesifo sorhudo esinganyangekiyo esimalunga ne-HIV kunye namavolontiya asempilweni afumana ukubola. Imicroecology Ther 1995; 25: 23-31.
  51. I-Potts L, i-Lewis SJ, kunye no-Barry R. Isifundo esilawulwa ngokungaqhelekanga se-placebo esilawula indawo ye-Saccharomyces boulardii ukukhusela urhudo olunxulumene ne-antibiotic [abstract]. Isisu 1996; 38 (suppl 1): A61.
  52. I-Bleichner G kunye ne-Blehaut H. Saccharomyces boulardii ithintela urhudo kwizigulana ezondla ngokugula zetyhubhu. Isilingo esilawulwa ngokungaqhelekanga, esingahleliwe, esingaboni kabini esilawulwa yi-placebo [abstract]. Iiklinikhi zeNutr 1994; 13 iSuppl 1:10.
  53. UMaupas JL, uChampemont P, kunye noDelforge M. [Unyango lwesifo esichaphazelayo samathumbu kunye neSaccharomyces boulardii - isifundo esilawulwa yimfama kabini]. UMédicine et Chirurgie Digestives 1983; 12: 77-79.
  54. I-Saint-Marc T, iBlehaut H, iMusial C, kunye no-al. [Urhudo olunxulumene noGawulayo: ulingo oluyimfama kabini lweSaccharomyces boulardii]. USemaine Des Hopitaux 1995; 71 (23-24): 735-741.
  55. IMcFarland LV, iSurawicz C, iGreenberg R, kunye okqhubekayo. I-Saccharomyces boulardii kunye nedosi ephezulu ye-vancomycin inyanga isifo esixhaphakileyo seClostridium difficile [abstract]. NdinguJ Gastroenterol 1998; 93: 1694.
  56. Chouraqui JP, Dietsch J, Musial C, kunye et al. I-Saccharomyces boulardii (SB) kulawulo lwesifo sorhudo esincinci: isifundo esilawulwa kabini esingaboniyo [indawo]. J Isidlangalala seGastroenterol Isondlo 1995; 20: 463.
  57. ICetina-Sauri G kunye neBasto GS. Uvavanyo lwe-terapeutica de Saccharomyces boulardii en ninos con diarrea aguda. Tribuna Med 1989; 56: 111-115.
  58. UAdam J, uBarret C, uBarret-Bellet A, kunye et al. Essais cliniques controles en double insu de l'Ultra-Levure Lyophilisee. Etude multicentrique par 25 medecins de 388 cas. IGaz Med Fr 1977; 84: 2072-2078.
  59. IMcFarland LV, iSurawiczCM, i-Elmer GW, kunye okqhubekayo. Uhlalutyo lweMultivariate lokusebenza ngempumelelo kweklinikhi yearhente ye-biotherapeutic, iSaccharomyces boulardii yokuthintela urhudo olunxulumene ne-antibiotic [abstract]. NdinguJ Epidemiol 1993; 138: 649.
  60. ISaint-Marc T, iRossello-Prats L, kunye neTouraine JL. [Ukusebenza kweSaccharomyces boulardii kulawulo lwesifo sorhudo lwe-AIDS]. UAnn Med Interne (eParis) ngo-1991; 142: 64-65.
  61. UKirchhelle, A., Fruhwein, N., kunye noToburen, D. [Unyango lwesifo sohudo oluqhubekayo kunye no-S. boulardii ekubuyeni kwabahambi. Iziphumo zophando olunokwenzeka]. I-Fortschr Med 4-20-1996; 114: 136-140. Jonga i-abstract.
  62. Uzalelwe, P., Lersch, C., Zimmerhackl, B., kunye noClassen, M. [Unyango lwe-Saccharomyces boulardii yonyango oluhambelana ne-HIV]. IDtsch Med Wochenschr 5-21-1993; 118: 765. Jonga i-abstract.
  63. UKollaritsch, H., Holst, H., Grobara, P., noWiedermann, G. [Ukuthintela urhudo lwabahambi ngeSaccharomyces boulardii. Iziphumo zesifundo se-placebo esilawulwa kabini esingaboni]. I-Fortschr. IMed 3-30-1993; 111: 152-156. Jonga i-abstract.
  64. Tempe, J. D., Steidel, A. L., Blehaut, H., Hasselmann, M., Lutun, P., kunye noMaurier, F. [Uthintelo lohudo olunika iSaccharomyces boulardii ngexesha lokutya rhoqo. Sem.Hop. 5-5-1983; 59: 1409-1412. Jonga i-abstract.
  65. UChapoy, P. [Unyango lwesifo sorhudo esibuhlungu esibuhlungu: ulingo olulawulwayo lweSaccharomyces boulardii]. UAnn Pediatr. (EParis) 1985; 32: 561-563. Jonga i-abstract.
  66. UKimmey, M.B, Elmer, G. W., Surawicz, C. M., kunye noMcFarland, L. V. Uthintelo lokuphinda kwenzeke kwakhona kwiClostridium difficile colitis eneSaccharomyces boulardii. Gqiba kwiDis Dis. 1990; 35: 897-901. Jonga i-abstract.
  67. Saint-Marc, T., Rossello-Prats, L., kunye noTouraine, J. L. [Ukusebenza kweSaccharomyces boulardii kunyango lwesifo sorhudo kwi-AIDS]. UAnn Med Interne (eParis) ngo-1991; 142: 64-65. Jonga i-abstract.
  68. UDuman, DG, Bor, S., Ozutemiz, O., Sahin, T., Oguz, D., Istan, F., Vural, T., Sandkci, M., Isksal, F., Simsek, mna, Soyturk. , M., Arslan, S., Sivri, B., Soykan, I., Temizkan, A., Bessk, F., Kaymakoglu, S., kunye noKalayc, C. Ukusebenza kunye nokukhuseleka kwe-Saccharomyces boulardii ekuthinteleni i-antibiotics- urhudo olunxulumene noko ngenxa yokupheliswa kweHelicobacterpylori. I-Eur J Gastroenterol, iHepatol. Ngo-2005; 17: 1357-1361. Jonga i-abstract.
  69. ISurawicz, C. M. Unyango lwezifo ezinxulunyaniswa ne-Clostridium difficile. Ukusebenza kweNat Clin. Gastroenterol, hepatol. Ngo-2004; 1: 32-38. Jonga i-abstract.
  70. I-Kurugol, Z. kunye neKoturoglu, G. Iziphumo zeSaccharomyces boulardii kubantwana abanesifo sorhudo. Acta Paediatr. 2005; 94: 44-47. Jonga i-abstract.
  71. UKotowska, M., Albrecht, P., kunye noSzajewska, H. Saccharomyces boulardii kuthintelo lohudo olunxulunyaniswa namayeza okubulala iintsholongwane ebantwaneni: ityala elilawulwa ngokungahleliwe elingaboniyo. Ukudibana.Pharmacol.Ther. 3-1-2005; 21: 583-590. Jonga i-abstract.
  72. I-Cherifi, S., Robberecht, J., kunye neMiendje, Y. Saccharomyces cerevisiae fungemia kwisigulana esikhulileyo esineClostridium difficile colitis. Iklinikhi yeActa Belg. Ngo-2004; 59: 223-224. Jonga i-abstract.
  73. I-Erdeve, O., Tiras, U., kunye neDallar, Y. Iziphumo zeprobiotic zeSaccharomyces boulardii kwiqela labantwana. J Trop. Isigulana. Ngo-2004; 50: 234-236. Jonga i-abstract.
  74. I-Costalos, C., Skouteri, V., Gounaris, A., Sevastiadou, S., Triandafilidou, A., Ekonomidou, C., Kontaxaki, F., kunye ne-Petrochilou, V. Ukutyisa abantwana abangaphambi kwexesha ngeSaccharomyces boulardii. Ukuqala kobuntu. Ngo-2003; 74: 89-96. Jonga i-abstract.
  75. UGaon, D., Garcia, H., Ubusika, L., Rodriguez, N., Quintas, R., Gonzalez, S. N., kunye no-Oliver, G. Iziphumo zeengxaki zeLactobacillus kunye neSaccharomyces boulardii kuhudo oluqhubekayo ebantwaneni. I-Medicina (B Aires) 2003; 63: 293-298. Jonga i-abstract.
  76. UMansour-Ghanaei, F., Dehbashi, N., Yazdanparast, K., noShafaghi, A. Ukusebenza kwe-saccharomyces boulardii ngamayeza okubulala iintsholongwane kwi-amoebiasis ebukhali. Kwihlabathi J Gastroenterol. Ngo-2003; 9: 1832-1833. Jonga i-abstract.
  77. URiquelme, A., uCalvo, uM, A., uGuzman, uA.M., Depix, M. S., Garcia, P., Perez, C., Arrese, M., kunye noLabarca, J. A. Saccharomyces cerevisiae fungemia emva konyango lweSaccharomyces boulardii kwizigulana ezingafakwanga emzimbeni. J Klinikhi yeGastroenterol. Ngo-2003; 36: 41-43. Jonga i-abstract.
  78. Cremonini, F., Di Caro, S., Santarelli, L., Gabrielli, M., Candelli, M., Nista, EC, Lupascu, A., Gasbarrini, G., kunye noGarbarrini, A. Iiprobiotiki ezinxulumene neyeza urhudo. Dig Dig, Isidibanisi sediski. 2002; 34 iSuppl 2: S78-S80. Jonga i-abstract.
  79. Lherm, T., Monet, C., Nougiere, B., Soulier, M., Larbi, D., Le Gall, C., Caen, D., kunye noMalbrunot, C. Amatyala asixhenxe e-fungemia ane-Saccharomyces boulardii ngokugxekayo abagulayo. Unonophelo olunzulu nge-2002; 28: 797-801. Jonga i-abstract.
  80. I-Tasteyre, A., Barc, M. C., Karjalainen, T., Bourlioux, P., kunye noCollignon, A. Inhibition ye vitro cell ukubambelela kweClostridium difficile yiSaccharomyces boulardii. Intsholongwane. Ngo-2002; 32: 219-225. Jonga i-abstract.
  81. UShanahan, F. Iiprobiotiki kwisifo esidlayo. Umjelo 2001; 48: 609. Jonga i-abstract.
  82. Surawicz, CM, McFarland, LV, Greenberg, RN, Rubin, M., Fekety, R., Mulligan, ME, Garcia, RJ, Brandmarker, S., Bowen, K., Borjal, D., kunye no-Elmer, GW khangela unyango olungcono lwezifo ezenzeka rhoqo zeClostridium difficile: ukusetyenziswa kwethamo eliphezulu le-vancomycin elidityaniswe neSaccharomyces boulardii. Iiklinikhi. Ngo-2000; 31: 1012-1017. Jonga i-abstract.
  83. UJohnston BC, Ma SSY, uGoldenberg JZ, et al. Iiprobiotic zokuthintela isifo sohudo esihambelana neClostridium difficile. UAnn Intern Med 2012; 157: 878-8. Jonga i-abstract.
  84. UMunoz P, uBouza E, uCuenca-Estrella M, et al. I-Saccharomyces cerevisiae fungemia: isifo esasulelayo esasulelayo. Iiklinikhi ezichaphazela iDis 2005; 40: 1625-34. Jonga i-abstract.
  85. I-Szajewska H, ​​i-Mrukowicz J. Uhlalutyo lwe-Meta: igwele elingeyo-pathogenic iSaccharomyces boulardii kuthintelo lohudo olunxulunyaniswa namayeza. Ukudibana kweFarmacol Ther 2005; 22: 365-72. Jonga i-abstract.
  86. Ngaba uM, uBesirbellioglu BA, uAvci IY, et al. Iprophylactic Saccharomyces boulardii kuthintelo lwesifo sorhudo esihambelana namayeza: Isifundo esinokwenzeka. IMed Sci Monit 2006; 12: PI19-22. Jonga i-abstract.
  87. UGuslandi M, uGiollo P, iTestoni PA. Uvavanyo lokulinga lwe-Saccharomyces boulardii kwi-ulcerative colitis. I-Eur J Gastroenterol Hepatol 2003; 15: 697-8. Jonga i-abstract.
  88. UGuslandi M, Mezzi G, Sorghi M, Testoni PA. Saccharomyces boulardii kunyango lwesifo sikaCrohn. Ukumba iDis Sci 2000; 45: 1462-4. Jonga i-abstract.
  89. IMcFarland LV. Uhlalutyo lwe-meta lweeprobiotic zokuthintela isifo esihambisa isifo esihambisa isifo kunye nokunyanga isifo seClostridium difficile. NdinguJ Gastroenterol 2006; 101: 812-22. Jonga i-abstract.
  90. UMarteau P, uSeksik P.Unyamezelo lweeprobiotic kunye ne-prebiotic. J Klinikhi yeGastroenterol 2004; 38: S67-9. Jonga i-abstract.
  91. U-Borriello SP, uHammes WP, uHolzapfel W, et al. Ukhuseleko lweeprobiotic eziqukethe i-lactobacilli okanye i-bifidobacteria. Iiklinikhi ezichaphazela iDis 2003; 36: 775-80. Jonga i-abstract.
  92. ICremonini F, uDi Caro S, uCovino M, et al. Ukuxhamla Iziphumo zamalungiselelo ahlukeneyo eproticotic kwi-anti-helicobacter pylori yeziphumo ezinxulumene nonyango: iqela elifanayo, iimfama ezintathu, isifundo esilawulwa yi-placebo. NdinguJ Gastroenterol 2002; 97: 2744-9. Jonga i-abstract.
  93. UD'Souza AL, uRajkumar C, uCooke J, uBulpitt CJ. Iiprobiotiki kuthintelo lohudo olunxulumene nesifo sorhudo: uhlalutyo lweemeta. BMJ 2002; 324: 1361. Jonga i-abstract.
  94. UMuller J, uRemus N, uHarms KH. Isifundo se-Mycoserological kunyango lwezigulana ze-cystic fibrosis yezigulana ezine-Saccharomyces boulardii (Saccharomyces cerevisiae Hansen CBS 5926). Mycoses 1995; 38: 119-23. Jonga i-abstract.
  95. I-Plein K, i-Hotz J. Iziphumo zonyango ze-Saccharomyces boulardii kwiimpawu ezisalele kancinci kwisigaba esizinzileyo sesifo sikaCrohn ngokuhlonipha ngokukodwa isifo sohudo esinganyangekiyo-isifundo somqhubi wenqwelomoya. Z Gastroenterol 1993; 31: 129-34. Jonga i-abstract.
  96. UHennequin C, uThierry A, uRichard GF, et al. Ukuchwetheza kweMicrosatellite njengesixhobo esitsha sokuchongwa kweengxaki zeSaccharomyces cerevisiae. J Iklinikhi yeMicrobiol 2001; 39: 551-9. Jonga i-abstract.
  97. UCesaro S, uChinello P, uRossi L, uZanesco L. Saccharomyces cerevisiae fungemia kwisigulana esine-neutropenic ephathwe nge-Saccharomyces boulardii. Inkxaso yeCancer Cancer 2000; 8: 504-5. Jonga i-abstract.
  98. U-Weber G, u-Adamczyk A, u-Freytag S. [Unyango lwe-acne ngokulungiselela igwele]. I-Fortschr Med 1989; 107: 563-6. Jonga i-abstract.
  99. U-Lewis SJ, uFreedman AR. Ukuphononongwa kwinqaku: ukusetyenziswa kweearhente zonyango kuthintelo kunye nonyango lwezifo zesisu. Ukudibana kweFarmacol Ther 1998; 12: 807-22. Jonga i-abstract.
  100. I-Krammer M, Karbach U. Antidiarrheal isenzo se-Saccharomyces boulardii kumqolo omncinci kunye namathumbu amakhulu ngokukhuthaza ukufakwa kwe-chloride. Z Gastroenterol 1993; 31: 73-7.
  101. ICzerucka D, Roux I, Rampal P. Saccharomyces boulardii inqanda imfihlo ye-adenosine 3 ', 5'-cyclic monophosphate induction kwiiseli zamathumbu. IGastroenterol 1994; 106: 65-72. Jonga i-abstract.
  102. UElmer GW, uMcFarland LV, uSurawicz CM, et al. Ukuziphatha kweSaccharomyces boulardii kwizigulana eziphindaphindayo zesifo seClostridium difficile. Ukudibana kweFarmacol Ther 1999; 13: 1663-8. Jonga i-abstract.
  103. UFredenucci I, uChomarat M, uBoucaud C, et al. I-Saccharomyces boulardii fungemia kwisigulana esifumana unyango lwe-ultra-levure. Iiklinikhi ezichaphazela iDis 1998; 27: 222-3. Jonga i-abstract.
  104. UPletinex M, Legein J, Vandenplas Y. Fungemia oneSaccharomyces boulardii kwintombazana eneminyaka eli-1 ubudala enesifo sorhudo esihambileyo. J Isidlangalala seGastroenterol Nutriti 1995; 21: 113-5. Jonga i-abstract.
  105. I-Buts JP, uCorthier G, uDelmee M. Saccharomyces boulardii weClostridium difficile enxulumene ne-enteropathies kwiintsana. J Isidlangalala seGastroenterol Nutriti 1993; 16: 419-25. Jonga i-abstract.
  106. I-Surawicz CM, i-Elmer GW, i-Speelman P, okqhubekayo. Uthintelo lohudo olunxulunyaniswa namayeza okubulala iintsholongwane nguSaccharomyces boulardii: isifundo esinokwenzeka. I-Gastroenterology 1989; 96: 981-8. Jonga i-abstract.
  107. ISurawicz CM, McFarland LV, Elmer G, et al. Unyango lwe-colostridium difficile colitis ephindaphindayo ene-vancomycin kunye ne-Saccharomyces boulardii. NdinguJ Gastroenterol 1989; 84: 1285-7. Jonga i-abstract.
  108. IMcFarland LV, iSurawicz CM, iGreenberg RN, okqhubekayo. Uthintelo lwe-beta-lactam olunxulumene nesifo sorhudo yi-Saccharomyces boulardii ngokuthelekiswa ne-placebo. NdinguJ Gastroenterol 1995; 90: 439-48. Jonga i-abstract.
  109. IMcFarland LV, iSurawicz CM, iGreenberg RN, okqhubekayo. Uvavanyo olulawulwa ngokungekho mthethweni lwe-placebo lwe-Saccharomyces boulardii ngokudibeneyo kunye namayeza aqhelekileyo esi sifo seClostridium difficile. IJAMA 1994; 271: 1913-8. Jonga i-abstract.
  110. UElmer GW, uMcFarland LV. Izimvo malunga nokusilela kunyango lwe-Saccharomyces boulardii kuthintelo lohudo olunxulumene nezifo kwizigulana esele zikhulile. J Ukuchaphazela i-1998; 37: 307-8. Jonga i-abstract.
  111. U-Lewis SJ, Potts LF, uBarry RE. Ukungabikho kwempembelelo yokunyanga kweSaccharomyces boulardii ekuthinteleni isifo sohudo esinxulumene ne-antibiotic kwizigulana ezigugileyo. J Ukuchaphazela i-1998; 36: 171-4. Jonga i-abstract.
  112. UBleichner G, uBlehaut H, uMentec H, et al. I-Saccharomyces boulardii ithintela urhudo kwizigulana ezinesifo esibuhlungu. Unonophelo olunzulu nge-1997; 23: 517-23. Jonga i-abstract.
  113. UCastagliuolo I, uRiegler MF, uValenick L, et al. Ukuchaneka I-Saccharomyces boulardii protease inqanda iziphumo ze-clostridium difficile toxins A kunye no-B kwi-colonic mucosa yabantu. Usulelo kunye no-Immun 1999; 67: 302-7. Jonga i-abstract.
  114. I-Saavedra J. Iiprobiotic kunye nesifo sorhudo esosulelayo. NdinguJ Gastroenterol 2000; 95: S16-8. Jonga i-abstract.
  115. IMcFarland LV. ISaccharomyces boulardii ayisiyiSaccharomyces cerevisiae. Iiklinikhi ezichaphazela iDis 1996; 22: 200-1. Jonga i-abstract.
  116. UMcCullough MJ, uClemons KV, uMcCusker JH, uStevens DA. Ukuchongwa kweentlobo kunye neempawu ezinobuzaza beSaccharomyces boulardii (nom. Inval.). J Iklinikhi yeMicrobiol 1998; 36: 2613-7. Jonga i-abstract.
  117. UNiault M, uThomas F, uProst J, et al. I-Fungemia ngenxa yeentlobo ze-Saccharomyces kwisigulana esinyangwe nge-enteral Saccharomyces boulardii. Iiklinikhi ezichaphazela iDis 1999; 28: 930. Jonga i-abstract.
  118. IBassetti S, Frei R, Zimmerli W. Fungemia eneSaccharomyces cerevisiae emva konyango ngeSaccharomyces boulardii. NdinguJ Med 1998; 105: 71-2. Jonga i-abstract.
  119. I-Scarpignato C, i-Rampal P. Uthintelo kunye nonyango lotyatyazo lomhambi: Indlela yeklinikhi yokuthambisa. I-Chemotherapy ngo-1995; 41: 48-81. Jonga i-abstract.
Ukuhlaziywa kokugqibela-11/10/2020

Ukukhetha Indawo

Yintoni i-Integrative Gynecology, Ngokuchanekileyo?
Indlela Yokuphila

Yintoni i-Integrative Gynecology, Ngokuchanekileyo?

I-CBD, i-acupuncture, um ebenzi wamandla-i-naturopathic kunye nokuba empilweni kweyona nto iphambili. Ngelixa uvavanyo lwakho lonyaka lwe-gynecological lu enokubakho ngokunyu a kunye ne- wab , inokuth...
Ulusu Olukhulu: Kwi-20s yakho
Indlela Yokuphila

Ulusu Olukhulu: Kwi-20s yakho

Khu ela, ukhu ele, ukhu ele i-mantra ye ikhumba e-20 .Qali a uku ebenzi a i- erum e ekwe kwi-antioxidant kunye neekhrim.Uphononongo luboni a ukuba i-antioxidant e etyenzi wa ngokwezihloko njengevitham...